Inhaled AR-501 in Adults with P. Aeruginosa Infected | Clinical Research Studies Listing

Inhaled AR-501 in Adults with P. Aeruginosa Infected Cystic Fibrosis Subjects

Recruiting

18 years - 49 years

All

Phase 1

5 participants needed

1 Location

Brief description of study

This is a study of AR-501 (gallium citrate) solution, administered via inhalation, in adults with P. aeruginosa infected cystic fibrosis (CF). The study will evaluate the safety and pharmacokinetic (PK) and efficacy of repeat administrations of inhaled AR-501 solution in P. aeruginosa infected CF.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: P. Aeruginosa Infected Cystic Fibrosis Subjects
Age: 18 years - 49 years
Gender: All

Male and Female, P. Aeruginosa Infected Cystic Fibrosis Subjects, Age 18-49

Updated on 04 Aug 2024. Study ID: 849607

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Inhaled AR-501 in Adults with P. Aeruginosa Infected Cystic Fibrosis Subjects

Brief description of study

Eligibility of study

Find a site

Interested in the study